Apeloa is honored to be listed 5th in the "2024 Top 20 China Pharmaceutical CDMO Companies," marking five consecutive years in the top five.

The "CDMO Ranking" is selected based on 10 criteria including annual revenue, net profit, R&D investment, personnel scale, brand recognition, and leadership in niche fields, representing the highest standards of China's pharmaceutical CDMO industry.

In recent years, Apeloa has been advancing technological innovation and increasing R&D investment, propelling our research capabilities and business expansion to new heights. We are committed to developing world-leading R&D Centers and Technology Platforms, consistently setting the standard for high-quality service in the global CDMO sector.